+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

  • PDF Icon

    Report

  • 179 Pages
  • April 2021
  • Region: Global
  • BIS Research
  • ID: 5313523
10% Free customization
Description Jump to:
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Market Segmentation
  • Commercialized Therapies: Imlygic, Oncorine, and RIGVIR
  • Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV
  • Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild-Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)
  • Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)

Regional Segmentation
  • North America: U.S.
  • Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)
  • Asia-Pacific - Japan, China, Rest-of-APAC (India, Australia, South Korea)

Growth Drivers
  • Increasing Incidence of Cancer
  • Rising Number of Clinical Trials
  • Increasing Research Funding from National Cancer Institute
  • Increasing Adoption of Inorganic Growth Strategies in the Market

Market Challenges
  • High Cost of Therapy
  • Lack of Therapy-Specific Assays

Market Opportunities
  • Opportunities in the Emerging Economies
  • Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

Key Companies Profiled

Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.

Key Questions Answered in this Report:
  • What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?
  • What are the key development strategies being implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?
  • How is each segment of the market expected to grow during the forecast period 2020-2030?
  • Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?
  • What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world?
  • What is the COVID-19 impact on the global oncolytic virus therapies market?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?
  • What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?
  • What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?
  • How is each segment of the market expected to grow during the forecast period 2020-2030?

The following are the segment types:
  • Commercialized Therapies
  • Pipeline Therapies
  • Type of Virus
  • Application
  • Region

Market Overview

Oncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body. These therapies aim at modifying genetic material for the treatment of a disease. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.

Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.

Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay. Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.

Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.

Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Oncolytic Virus Therapies Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 Market Overview
4.1 Market Definition
4.2 Importance of Oncolytic Virus Therapies in Cancer Treatment
4.3 Market Size and Growth Potential, $Million, 2019-2030
4.4 COVID-19 Impact on the Global Oncolytic Virus Therapies Market
5 Industry Insights
5.1 Overview
5.2 Regulatory Scenario
5.3 Legal Requirements and Framework in the U.S
5.3.1 Clinical Trial Authorization
5.3.2 U.S. FDA Guidelines for BLA Submission
5.4 Legal Requirements and Framework in Europe
5.4.1 EMA Biologics License Application Process
5.4.2 Centralized Procedure
5.4.3 Decentralized Procedure
5.4.4 Mutual-Recognition Procedure
5.5 Legal Requirements and Framework in Asia-Pacific
5.5.1 China
5.5.2 Japan
5.6 Expedited Regulatory Designations Around the World
5.7 Reimbursement Scenario
5.8 Patent Analysis
5.8.1 Patent Filing Trend
6 Market Dynamics
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Increasing Incidence of Cancer
6.3.2 Rising Number of Clinical Trials
6.3.3 Increasing Research Funding from National Cancer Institute
6.3.4 Increasing Adoption of Inorganic Growth Strategies in the Market
6.4 Market Restrains
6.4.1 High Cost of Therapy
6.4.2 Lack of Therapy-Specific Assays
6.5 Market Opportunities
6.5.1 Opportunities in the Emerging Economies
6.5.2 Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies
7 Competitive Landscape
7.1 Synergistic Activities
7.2 Business Expansion Activities and Others
7.3 Product Launches and Product Updates
7.4 Mergers and Acquisitions
7.5 Market Share Analysis
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Commercialized Therapy)
8 Oncolytic Virus Therapies: Epidemiology Analysis
9 Global Oncolytic Virus Therapies Market (by Commercialized Therapies), $Million, 2019-2030
9.1 Overview
9.2 Imlygic
9.3 Oncorine
9.4 RIGVIR
10 Global Oncolytic Virus Therapies Market (by Pipeline Therapies), $Million, 2019-2030
10.1 Overview
10.2 Phase I
10.3 Phase II
10.4 Phase III
10.5 Phase IV
11 Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030
11.1 Overview
11.2 Genetically Engineered Oncolytic Virus
11.2.1 Herpes Simplex Virus (HSV)
11.2.2 Adenovirus
11.2.3 Vaccinia Virus
11.3 Oncolytic Wild-Type Virus
11.3.1 Reovirus (Respiratory Enteric Orphan Virus)
11.3.2 Newcastle Disease Virus (NDV)
11.3.3 Vesicular Stomatitis Virus (VSV)
12 Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
12.1 Overview
12.2 Solid Tumor
12.2.1 Breast Cancer
12.2.2 Prostate Cancer
12.2.3 Lung Cancer
12.2.4 Glioblastoma
12.2.5 Melanoma
12.2.6 Other Applications
12.3 Hematological Malignancies
12.3.1 Lymphoma
12.3.2 Leukemia
12.3.3 Myeloma
13 Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
13.1 Overview
13.2 North America
13.2.1 U.S.
13.3 Europe
13.3.1 U.K.
13.3.2 Latvia
13.3.3 Georgia
13.3.4 Armenia
13.3.5 Germany
13.3.6 France
13.3.7 Italy
13.3.8 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.3 Rest-of-APAC
14 Company Profiles
14.1 Overview
14.2 Amgen Inc.
14.2.1 Company Overview
14.2.2 Role of Amgen Inc. in the Global Oncolytic Virus Therapies Market
14.2.3 Financials
14.2.4 Key Insights about Financial Health of the Company
14.2.5 SWOT Analysis
14.3 DAIICHI SANKYO COMPANY, LIMITED
14.3.1 Company Overview
14.3.2 Role of DAIICHI SANKYO COMPANY, LIMITED in the Global Oncolytic Virus Therapies Market
14.3.3 Financials
14.3.4 Key Insights About Financial Health of the Company
14.3.5 SWOT Analysis
14.4 DNAtrix
14.4.1 Company Overview
14.4.2 Role of DNAtrix in the Global Oncolytic Virus Therapies Market
14.4.3 SWOT Analysis
14.5 Genelux
14.5.1 Company Overview
14.5.2 Role of Genelux in the Global Oncolytic Virus Therapies Market
14.5.3 SWOT Analysis
14.6 Oncolytics Biotech, Inc.
14.6.1 Company Overview
14.6.2 Role of Oncolytics Biotech, Inc. in the Global Oncolytic Virus Therapies Market
14.6.3 Financials
14.6.4 SWOT Analysis
14.7 PsiOxus Therapeutics
14.7.1 Company Overview
14.7.2 Role of PsiOxus Therapeutics in the Global Oncolytic Virus Therapies Market
14.7.3 SWOT Analysis
14.8 RIGVIR Ltd.
14.8.1 Company Overview
14.8.2 Role of RIGVIR Ltd. in the Global Oncolytic Virus Therapies Market
14.8.3 SWOT Analysis
14.9 Shanghai Sunway Biotech Co., Ltd.,
14.9.1 Company Overview
14.9.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Oncolytic Virus Therapies Market
14.9.3 SWOT Analysis
14.1 SillaJen, Inc.
14.10.1 Company Overview
14.10.2 Role of SillaJen, Inc. in the Global Oncolytic Virus Therapies Market
14.10.3 SWOT Analysis
14.11 Sorrento Therapeutics, Inc.
14.11.1 Company Overview
14.11.2 Role of Sorrento Therapeutics, Inc. in Global Oncolytic Virus Therapies Market
14.11.3 Financials
14.11.4 Key Insights About Financial Health of the Company
14.11.5 SWOT Analysis
14.12 Takara Bio Inc.
14.12.1 Company Overview
14.12.2 Role of Takara Bio Inc. in the Global Oncolytic Virus Therapies Market
14.12.3 Financials
14.12.4 Key Insights About Financial Health of the Company
14.12.5 SWOT Analysis
14.13 Transgene sa
14.13.1 Company Overview
14.13.2 Role of Transgene sa in the Global Oncolytic Virus Therapies Market
14.13.3 Financials
14.13.4 SWOT Analysis
14.14 VCNBiosciences
14.14.1 Company Overview
14.14.2 Role of VCNBiosciences in the Global Oncolytic Virus Therapies Market
14.14.3 SWOT Analysis
14.15 ViroCure
14.15.1 Company Overview
14.15.2 Role of ViroCure in the Global Oncolytic Virus Therapies Market
14.15.3 SWOT Analysis
14.16 Viralytics Ltd. (Merck & Co., Inc.)
14.16.1 Company Overview
14.16.2 Role of Merck & Co., Inc. in the Global Oncolytic Virus Therapies Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
List of Tables
Table 5.1: Regulatory Scenario Across the World
Table 5.2: Expedited Regulatory Designations Around the World
Table 5.3: Key Market Access Landscape (by Country), January 2019
Table 9.1: Commercialized Therapies
Table 10.1: Key Oncolytic Virus Therapies in Clinical Development Phase I, 2020
Table 10.2: Key Oncolytic Virus Therapies in Clinical Development Phase II, 2020
Table 10.3: Key Oncolytic Virus Therapies in Clinical Development Phase III, 2020
Table 11.1: Key Herpes Simplex Virus (HSV)-Based Oncolytic Therapies
Table 11.2: Key Adenovirus-Based Oncolytic Therapies
Table 11.3: Key Vaccinia Virus-Based Oncolytic Therapies
Table 11.4: Key Reovirus-Based Oncolytic Therapies
Table 13.1: Rest-of-APAC - Pipeline Drugs
List of Figures
Figure 1: NCI Fiscal Budget Year on Year, 2013-2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Oncolytic Virus Therapies Market
Figure 3: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019 Vs. 2030
Figure 4: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019 vs. 2030
Figure 5: Global Oncolytic Virus Therapies Market Snapshot, $Million, 2019 and 2030
Figure 2.1: Global Oncolytic Virus Therapies Market Segmentation
Figure 3.1: Global Oncolytic Virus Therapies Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 4.2: Global Oncolytic Virus Therapies Market: COVID-19 Impact
Figure 5.1: Clinical Trial Authorization for Oncolytic Virus Therapies
Figure 5.2: Steps for Obtaining Marketing Authorization
Figure 5.3: U.S. FDA Expedited Review Programs
Figure 5.4: Regulatory Strategy for Oncolytic Virus Therapies in the U.S.
Figure 5.5: U.S.FDA Review Timeline
Figure 5.6: Regulatory Strategy for Oncolytic Virus Therapies in Europe
Figure 5.7: EMA Review Timeline
Figure 5.9: Overview of PMDA and MLHW Drug Approval Process in Japan
Figure 5.10: Global Oncolytic Virus Therapies Market: Patent Analysis (by Country and Year), January 2015-March 2021
Figure 6.1: Impact Analysis
Figure 6.2: Cancer Cases Projection, 2016-2020
Figure 6.3: Number of Active and Completed Clinical Trials for Gene Therapy (by Start Date), 2015-2019
Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 6.5: NCI Fiscal Budget Year-on-Year, 2013-2018
Figure 6.6: Synergistic Activities, 2018-2020
Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021
Figure 7.2: Synergistic Activities Share (by Company), January 2018-March 2021
Figure 7.3: Business Expansion Activities Share (by Company), January 2018-March 2021
Figure 7.4: Number of Product Launches (by Company), January 2018-March 2021
Figure 7.5: Mergers and Acquisitions, January 2018-March 2021
Figure 7.6: Market Share Analysis for Global Oncolytic Virus Therapies Market, (by Application), $Million, 2020
Figure 7.7: Growth Share Analysis for Global Oncolytic Virus Therapies Market (by Commercialized Therapy), 2019-2020
Figure 8.1: Type of Cancer
Figure 8.2: Global Estimated Percent of New Cancer Cases (by Sex), 2030
Figure 8.3: Expected Cancer Cases in the World (by Country), 2030
Figure 8.4: Relative Number of Expected New Cancer Cases (by Country), 2030
Figure 9.1: Global Oncolytic Virus Therapies Market (Imlygic), $Million, 2019-2030
Figure 9.2: Global Oncolytic Virus Therapies Market (Oncorine), $Million, 2019-2030
Figure 9.3: Global Oncolytic Virus Therapies Market (RIGVIR), $Million, 2019-2030
Figure 10.1: Oncolytic Virus Gene Therapy Medicines in Development (by Disease), 2019
Figure 11.1: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030
Figure 11.2: Global Oncolytic Virus Therapies Market (by Genetically Engineered Oncolytic Virus), $Million, 2019 and 2030
Figure 11.3: Global Oncolytic Virus Therapies Market (Herpes Simplex Virus), $Million, 2019-2030
Figure 11.4: Global Oncolytic Virus Therapies Market (Adenovirus), $Million, 2019-2030
Figure 11.5: Global Oncolytic Virus Therapies Market (Vaccinia Virus), $Million, 2019-2030
Figure 11.6: Global Oncolytic Virus Therapies Market (by Oncolytic Wild-Type Virus), $Million, 2019 and 2030
Figure 11.7: Global Oncolytic Virus Therapies Market (Reovirus), $Million, 2019-2030
Figure 11.8: Global Oncolytic Virus Therapies Market (Newcastle Disease Virus), $Million, 2019-2030
Figure 11.9: Global Oncolytic Virus Therapies Market (Vesicular Stomatitis Virus), $Million, 2019-2030
Figure 12.1: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
Figure 12.2: Global Oncolytic Virus Therapies Market (by Solid Tumor), $Million, 2019 and 2030
Figure 12.3: Global Oncolytic Virus Therapies Market (Breast Cancer), $Million, 2019-2030
Figure 12.4: Global Oncolytic Virus Therapies Market (Prostate Cancer), $Million, 2019-2030
Figure 12.5: Global Oncolytic Virus Therapies Market (Lung Cancer), $Million, 2019-2030
Figure 12.6: Global Oncolytic Virus Therapies Market (Glioblastoma), $Million, 2019-2030
Figure 12.7: Global Oncolytic Virus Therapies Market (Melanoma), $Million, 2019-2030
Figure 12.8: Global Oncolytic Virus Therapies Market (Other Applications), $Million, 2019-2030
Figure 12.9: Global Oncolytic Virus Therapies Market (by Haematological Malignancies), $Million, 2019 and 2030
Figure 12.10: Global Oncolytic Virus Therapies Market (Lymphoma), $Million, 2019-2030
Figure 12.11: Global Oncolytic Virus Therapies Market (Leukemia), $Million, 2019-2030
Figure 12.12: Global Oncolytic Virus Therapies Market (Myeloma), $Million, 2019-2030
Figure 13.1: Global Oncolytic Virus Therapies Market (by Region), 2019-2030
Figure 13.2: Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
Figure 13.3: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2019
Figure 13.4: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2030
Figure 13.5: North America Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.6: North America: Market Dynamics
Figure 13.7: U.S. Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.8: Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.9: Europe: Market Dynamics
Figure 13.10: Europe Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
Figure 13.11: U.K. Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.12: Latvia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.13: Georgia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.14: Armenia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.15: Germany Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.16: France Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.17: Italy Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.18: Rest-of-Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.19: Asia-Pacific Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.20: APAC: Market Dynamics
Figure 13.21: APAC Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
Figure 13.22: China Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.23: Japan Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.24: RoAPAC Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Amgen Inc.: Product Portfolio
Figure 14.3: Amgen Inc.: Overall Financials, $Million, 2018-2020
Figure 14.4: Amgen Inc.: Revenue (by Region), $Million, 2018-2020
Figure 14.5: Amgen Inc. R&D Expenditure, $Billion, 2018-2020
Figure 14.6: Amgen Inc.: SWOT Analysis
Figure 14.7: DAIICHI SANKYO COMPANY, LIMITED: Product Portfolio
Figure 14.8: DAIICHI SANKYO COMPANY, LIMITED: Overall Financials, $Billion, 2017-2019
Figure 14.9: Amgen Inc. R&D Expenditure, $Billion, 2017-2019
Figure 14.10: DAIICHI SANKYO COMPANY, LIMITED: SWOT Analysis
Figure 14.11: DNAtrix: Product Portfolio
Figure 14.12: DNAtrix: SWOT Analysis
Figure 14.13: Genelux: Product Portfolio
Figure 14.14: Genelux: SWOT Analysis
Figure 14.15: Oncolytics Biotech, Inc.: Product Portfolio
Figure 14.16: Oncolytics Biotech, Inc.: SWOT Analysis
Figure 14.17: PsiOxus Therapeutics: Pipeline Product Portfolio
Figure 14.18: PsiOxus Therapeutics: SWOT Analysis
Figure 14.19: RIGVIR Ltd.: Overall Service Portfolio
Figure 14.20: RIGVIR Ltd.: SWOT Analysis
Figure 14.21: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 14.22: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 14.23: SillaJen, Inc.: Product Portfolio
Figure 14.24: SillaJen, Inc.: SWOT Analysis
Figure 14.25: Sorrento Therapeutics, Inc.: Product Portfolio
Figure 14.26: Sorrento Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 14.27: Sorrento Therapeutics, Inc. R&D Expenditure, $Million, 2017-2019
Figure 14.28: Sorrento Therapeutics, Inc.: SWOT Analysis
Figure 14.29: Takara Bio Inc.: Product Portfolio
Figure 14.30: Takara Bio Inc.: Overall Financials, 2017-2019
Figure 14.31: Takara Bio Inc.: Revenue (by Segment), $Million, 2017-2019
Figure 14.32: Takara Bio Inc.: Revenue (by Region), $Million, 2017-2019
Figure 14.33: Takara Bio Inc.: R&D Expenditure, 2017-2019
Figure 14.34: Takara Bio Inc.: SWOT Analysis
Figure 14.35: Transgene sa: Product Portfolio
Figure 14.36: Transgene sa: Overall Financials, $Million, 2017-2019
Figure 14.37: Transgene sa: SWOT Analysis
Figure 14.38: VCNBiosciences: Pipeline Product Portfolio
Figure 14.39: VCNBiosciences: SWOT Analysis
Figure 14.40: ViroCure: Product Portfolio
Figure 14.41: ViroCure: SWOT Analysis
Figure 14.42: Viralytics Ltd., (Merck & Co., Inc.): Product Portfolio
Figure 14.43: Merck & Co., Inc.: Overall Financials, $Million, 2018-2020
Figure 14.44: Merck & Co., Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 14.45: Merck & Co., Inc.: Revenue (by Region), $Million, 2018-2020
Figure 14.46: Merck & Co., Inc.: R&D Expenditure, $Million, 2018-2020
Figure 14.47: Merck & Co., Inc.: SWOT Analysis

Companies Mentioned

  • Amgen Inc.
  • DAIICHI SANKYO COMPANY, LIMITED
  • DNAtrix
  • Genelux
  • Oncolytics Biotech, Inc.
  • PsiOxus Therapeutics
  • RIGVIR Ltd.
  • Shanghai Sunway Biotech Co., Ltd.,
  • SillaJen, Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Transgene sa
  • VCNBiosciences
  • ViroCure
  • Viralytics Ltd. (Merck & Co., Inc.)

Related Topics

Related Reports

Oncolytic Virus Therapies Market Report by Virus Type, Application, End Use, and Region 2024-2032 - Product Image

Oncolytic Virus Therapies Market Report by Virus Type, Application, End Use, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Oncolytic Virus Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023-2031 - Product Image

Oncolytic Virus Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023-2031

  • Report
  • 112 Pages
  • Global
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024 - Product Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024

  • Clinical Trials
  • 280 Pages
  • Global
From
Oncolytic Virus Therapy Global Market Report 2024 - Product Image

Oncolytic Virus Therapy Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Oncolytic Virus Therapies Market by Virus Type, Application, End Use - Global Forecast 2025-2030 - Product Image

Oncolytic Virus Therapies Market by Virus Type, Application, End Use - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.